Xichui zong tong shi lue : [12 juan] /

On double leaves, oriental style, in case.Latest preface dated: 1809.Includes: [1] Xi chui zhu zhi ci. -- [2] Sui fu ji lue tu shi.Mounted case title: Jiaqing Xinjiang Xichui zong tong shi lue.Mode of access: Internet

Effect of neoadjuvant chemotherapy in patients with resectable colorectal liver metastases.

BACKGROUND: Whether patients with resectable colorectal liver metastases (CRLM) receive survival benefit from neoadjuvant chemotherapy remains controversial. METHODS: We retrospectively analyzed 466 patients with resectable CRLM between 2000 and 2010. Patient characteristics and survival data were recorded. RESULTS: The patients were divided into one group with neoadjuvant chemotherapy (group NC, n = 121) and another without (group WN, n = 345). There was no difference in 5-year survival (52% vs. 48%) between the two groups. No significant differences were identified between the two groups in terms of 30-day mortality (1.7% vs. 1.2%) or morbidity (33.9% vs. 25.8%). A primary tumor at stage T4, ≥4 liver metastases, the largest liver metastasis ≥5 cm in diameter, and a serum CEA level ≥5 ng/ml were independent prognostic factors. By assigning one point to each, the patients were divided into a low-risk group (0-2) and a high-risk (3-4). The patients in the low-risk group received no survival benefit from neoadjuvant chemotherapy, whereas those in the high-risk group received survival benefit (5-year survival, 39% vs. 33%, P = 0.028). CONCLUSIONS: Preoperative neoadjuvant chemotherapy did not increase mortality or complications. Not all resectable patients, only those with >2 independent risk factors, received survival benefit from neoadjuvant chemotherapy

Open Right Hemicolectomy:Lateral to Medial or Medial to Lateral Approach?

Currently, no published studies have compared the clinical outcomes of the medial-to-lateral approach (MA) and lateral-to-medial approach (LA) for open right hemicolectomy. Thus, the present study aimed to assess whether one of these approaches has any potential benefits over the other.A retrospective study was performed of all patients who underwent open right hemicolectomy with pathologically confirmed disease who met the eligibility criteria between June 2008 and June 2012. The population was divided into an MA group and an LA group by propensity scoring. We compared patient demographic and clinical characteristic variables between the two groups and assessed short-term and long-term outcomes.A total of 450 patients (MA, n = 150; LA, n = 300) were evaluated. The operation time (MA,138.4 minutesvs.LA,166.2 minutes; P < .05) and blood loss (MA,52.0mL vs. LA,62.6mL; P < .05)were significantly lower in the MA group. No differences in the number of harvested lymph nodes and oncologic outcomes were observed between the two groups. Further subgroup analysis for stage III colon cancer revealed that the MA group had significantly more retrieved lymph nodes (MA,18.8vs. LA,16.0; P = .028). There were no differences in other variables between the two groups.The MA reduced operative time and blood loss compared with the LA. We thus concluded that the MA provided short-term benefits compared with the LA in open right hemicolectomy for right-sided colon cancer

Clinicopathological characteristic associated with overall survival.

<p>Clinicopathological characteristic associated with overall survival.</p

Clinicopathologic characteristics of patients with resectable CRLM.

<p>Clinicopathologic characteristics of patients with resectable CRLM.</p

Survival of patients with resectable CRLM after liver resection.

<p><a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0086543#pone-0086543-g001" target="_blank">Fig. 1A</a> Kaplan–Meier curves illustrating survival of all patients with resectable CRLM after liver resection. A total of 466 resectable patients had a median survival of 56.1 months and a 5-year survival rate of 49%. <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0086543#pone-0086543-g001" target="_blank">Fig. 1B</a> Kaplan–Meier curves illustrating survival of resectable patients with or without neoadjuvant chemotherapy. 121 patients with neoadjuvant chemotherapy had a median survival of 60.0 months and a 5-year survival rate of 52%, whereas those without neoadjuvant chemotherapy had a similar median survival of 53.4 months and a 5-year survival rate of 48%. <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0086543#pone-0086543-g001" target="_blank">Fig. 1C</a> Kaplan–Meier curves illustrating survival of low-risk patients with or without neoadjuvant chemotherapy. In the low-risk group, the patients with and without neoadjuvant chemotherapy had similar survival (median survival, 60.0 m vs. 60.0 m; 5-year survival, 64% vs. 57%; P>0.05). <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0086543#pone-0086543-g001" target="_blank">Fig. 1D</a> Kaplan–Meier curves illustrating survival of high-risk patients with or without neoadjuvant chemotherapy. In the high-risk group, patients who had received neoadjuvant chemotherapy had a better overall median survival (38.9 m vs. 28.4 m) and a more favorable 5-year overall survival (39% vs. 33%; P = 0.028) than those had not received neoadjuvant chemotherapy.</p

Pathology Data.

<p>Pathology Data.</p

Baseline Patient Demographics and Clinical Characteristics.

<p>Baseline Patient Demographics and Clinical Characteristics.</p

Perioperative outcomes and complications.

<p>Perioperative outcomes and complications.</p